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Initial surgical management is commonly accepted to date as paramount in the treatment of women presenting with epithelial
ovarian cancer and permits the assessment of the disease (staging), the histological confirmation of disease type and grade, and
the practice of maximal debulking preceding platinum-based chemotherapy. Many studies have shown that the volume of residual
disease after initial surgical cytoreduction inversely correlates with survival. Thus, women with optimal debulking performed by
a trained specialist have improved median survival. In this review, we will focus on the answers gleaned from clinical trials on
primary and interval surgery, which prompts the question on the timing of surgery in respect to chemotherapy. Interval debulking
surgery (IDS) is secondary cytoreduction following primary debulking and is carried out in between the courses of chemotherapy.
The major clinical trials and the latest systematic reviews seem unable to give any definitive guidance or recommendation for
clinical practice. The choice of aggressive primary cytoreduction or upfront chemotherapy followed by second line surgical
cytoreduction seems among others to have to be individualized according to tumour load, prediction of its resectability, and
response to chemotherapy. The role of tumour biology must also be kept in mind. Finally, concrete answers are awaited on the
timing of surgery from the ongoing prospective randomized control trials (CHORUS and EORTC 55971) though preliminary data
from the latter have already been presented at major meetings (IGCS 2008; SGO 2009) and ignited strong debate.
1. Introduction
Ovarian cancer represents the sixth most commonly diag-
nosed cancer among women in the world and causes more
deaths per year than any other cancer of the female reproduc-
tive system [1]. In advanced disease which constitutes about
75% of women at presentation, the accepted management is
a combination of surgery and platinum based chemotherapy.
This has been the approach for some decades, though the 5-
year survival remains poor at about 40%. Epithelial ovarian
cancer constitutes the majority of disease types, and this
review will focus on reports relating to advanced epithelial
ovarian carcinoma.
2. Materials and Methods
A Medline database search (January 1966 to April 2009)
was undertaken using key words: epithelial ovarian cancer,
debulking surgery, and interval debulking surgery resulting
in 80 articles with 14 relevant papers. The articles in full were
obtained for each of the papers and reviewed by the authors.
Results in terms of overall survival (OS) and progression free
survival (PFS) were evaluated in each study.
3. Results
The 80 resulting articles were screened and 14 relevant papers
were retained: 3 meta-analysis [2–4], 3 randomized control
trials (RTC) [5–7] (Table 1) 2 Cochrane Reviews (CRs) [8,
9], and 6 case/control (CC) reports enrolling more than 50
patients [10–15] (Table 2).
4. Discussion
4.1. Primary Debulking Surgery. The initial studies support-
ing the concept of debulking surgery were published in the
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Table 1: RCTs investigating the role of IDS.
Name of Study
& year
Rose PG et al. [6] (GOG)
Van der Burg et al. [5]
(EORTC)
Redman et al.
19941 [7]
N
550 with 448
randomized 226 IDS
versus 222 no IDS
425 with 319
randomized 278
evaluated: 138 IDS
versus 140 no IDS
86 randomized
with 7 excluded∗37
IDS42 no IDS
FIGO stage II-IV IIB-IV II-IV
Trial
characteristics
RD > 1 cm after primary
surgery and
responding/stable after 3
cycles of
Cisplatin/pacitaxelStage
IV only pleural eﬀusion
RD > 1 cm & maximum
primary debulking not
attempted in all cases
with high proportion of
RD >5 cm
Randomization after 3
cycles of CP
Primary surgery
and RD > 2 cm 1–4
CP Or 3 PAB
followed by 5∗
escalating CP
PFS for IDS
versus No IDS
12.5 versus 12.7 18 versus 13
OS for IDS
versus No IDS
36.2 versus 35.7 26 versus 20
15 versus 12
months
CP: cisplatin/cyclophosphamide; overall survival in months; PAB: cyclophosphamide/doxorubicine/bleomycin; PSF: progression free survival in months; RD:
residual disease.
∗Surgery was non suboptimum.
1
Randomization begins at the start of the trial.
1970s by Griﬃths et al. [16]. The premise for considering
the potential impact of reducing intra-abdominal tumour
burden was based on the findings of work by Magrath et al.
[17], which reported enhanced survival outcome by reducing
intra-abdominal disease, in patients with Hodgkin’s disease.
Griﬃths undertook a retrospective analysis of just over 100
women and noted that those with residual disease masses
<1.6 cms in largest diameter had an improved survival
outcome compared with patients left with a greater disease
volume. A subsequent small prospective study [18] on
a heterogeneous population of patients, who underwent
aggressive radical surgery, also revealed the better survival
pattern associated with less tumour burden. Thus, the
concept of debulking surgery in ovarian cancer became
the normal approach to this disease. The use of adjuvant
chemotherapy, which is platinum based, is also the accepted
norm in care. The question as to whether the surgical ability
of the operator or the inherent tumour biology of the
disease is the main factor impacting on survival remains a
debate. Indeed, the benefit of radical debulking has already
come under criticism [19] while some have advocated
that tumour biology rather than the surgical eﬀort might
determine prognosis [20]. In a study of 213 patients with
Stage IIIC epithelial ovarian cancer who underwent complete
cytoreduction before initiation of systemic platinum-based
combination chemotherapy, Eisenkop and Spirtos [21] came
to the conclusion that the need to remove a large number of
peritoneal implants correlates with biological aggressiveness
and diminished survival, but not significantly enough to
preclude long-term survival or justify abbreviation of the
operative eﬀort.
Regarding primary surgery, there is a plethora of
published papers, all of which support the findings of
Griﬃths, though none are randomized controlled trials, and
hence, all with similar inherent biases. It is also important
to note that various definitions of optimal cytoreduction
have been proposed [22–24]. The Gynaecologic Oncology
Group (GOG) currently defines optimal cytoreduction as
leaving residual disease less than 1 cm in maximum tumour
diameter. Some may argue that optimum should only mean
no macroscopic residual disease.
There are 3 systematic reviews on residual disease
and outcome, which have conflicting conclusions. In an
analysis of 81 cohorts of patients (over 6000 women) with
advanced-stage ovarian carcinoma treated with platinum-
based chemotherapy Bristow et al. [4] found a 5.5-percent
increase in median survival for every 10-percent increase in
the proportion of patients achieving maximal cytoreduction.
Contrary to these findings was the meta-analysis by Hunter
et al. [2], (again over 6000 women) whereby the administra-
tion of platinum was deemed more important in influencing
survival rather than the achievement of optimum debulking
surgery. The main diﬀerence between these papers is that
in Bristow’s study, all patients were exposed to adjuvant
platinum therapy, which was not the case in Hunters
study. The third and smaller study also concluded that
optimum debulking was associated with improved survival
patterns, though further prospective trials were necessary
[3].
4.2. Secondary Surgical Cytoreduction. At the beginning
of the eighties, Berek et al. [25] noticed that secondary
cytoreduction could also improve survival. Subsequently, the
role of interval debulking surgery (IDS) has been investigated
in three prospective Randomized Controlled Trials (RCTs)
[5–7] where conclusions are diﬀerent. Interval debulking
surgery is defined as a second operation performed after 3
or 4 cycles of platinum chemotherapy in woman who had
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Table 2: Nonrandomized case control studies evaluating delayed primary debulking surgery.
Name of Study
Colombo et al.
[10]
Oksefjell et al. [11] Hegazy et al. [12] Le T et al. [13] Rafii et al. [14] Vergote [15]
N 203
789(217 IDS 572
non IDS)
59 all submitted to prior
surgical exploration
61 109 285
FIGO stage IIc-IV
All stages treated
for 1st relapse
II-IV
IV without bowel
obstruction
IV III-IV
Important study
data
Gr 1 conventional
OS = 38m Gr 2
with NACT OS =
26m
Platinum single or
combination/taxol
single or
combinationor
other
N = 27 (OS = 25 m)
unresectable NACT with
18 for IDSN = 32
primary cytoreduction
(OS = 28)
NACT
platinum-taxol OS
= 41.7m
NACT platinum-
taxol + IDSOS =
45.5m (under 20%
of patients in
study)
Choice of
treatment:
upfront
surgery or
NACT
according to
disease extent
and patient
PPS
Main
conclusions
Upfront surgery for
advanced operable
disease
Benefit of IDS
versus
chemotherapy
alone when
tumour is
localised.
NACT for unresectable
tumours leads to a group
of sensitive patients for
successful IDS
Response rate to
NACT comparable
to that of upfront
surgery stated in
literature
Benefit of IDS in
patient responding
to NACT
OS was
higher for
patients with
high tumour
load treated
with NACT
than with
upfront
surgery
NACT for non
operable or poor
performance status
with IDS ideally
after 3 cycles
Best OS (48m)
with radical
primary
cytoreduction, TFI
>24m &≤ 39 years
Importance of
maximal secondary
cytoreduction in
IDS
NACT can select
patients for surgery
IDS: interval debulking surgery; m = months; NACT: neoadjuvant chemotherapy; OS: overall survival; PFS: progression free survival; PPS: patient
performance status; TFI: treatment free interval.
suboptimal debulking primary surgery. Table 1 summarizes
the main features of these trials.
The trials by Redman et al. [7] and the GOG by
Rose et al. [6] failed to show any advantage of IDS. The
study by Redman was closed prematurely, as no survival
benefit was noted at interim analysis, and of note, optimum
debulking was defined as <2 cms residium compared with
<1 cms in the other studies. In the GOG study, 550 women
with suboptimally debulked stage III/IV ovarian cancer
received three cycles of paclitaxel/cisplatin and then were
randomly assigned to interval cytoreduction or no surgery.
Chemotherapy was continued up to a maximum of 6 cycles.
A secondary attempt at cytoreduction was not associated
with an improvement in progression free survival (PFS) (12.5
versus 12.7 months) or overall survival (OS) (36.2 versus
35.7 months). This was not the case with the EORTC trial
carried out by Van de Burg et al. [5], which showed that the
IDS group had a significantly increased median survival of 6
months compared to those who had not undergone this pro-
cedure. Indeed this is still the only prospective RCT showing
a survival benefit with “debulking” surgery. Nevertheless, it is
important to point out some diﬀerences between these trials.
At the time of the EORTC trial, chemotherapy consisted of
cisplatin/cyclophosphamide as Paclitaxel was not available,
unlike the GOG trial. Another major diﬀerence was that
in the EORTC trial, primary surgery was not necessarily
performed by a trained gynaecological oncologist, resulting
in diﬀerent extents of debulking. The number of patients
with less than 5 cm of residual tumour following primary
cytoreduction in the EORTC trial was less than a third, com-
pared to 55 percent in the GOG trial. Surgery performed by a
trained gynaecological oncologist has been shown to increase
survival [26], and the GOG study therefore concludes that
with appropriate persons undertaking primary surgery, IDS
is not required.
4.3. Neoadjuvant Chemotherapy (NACT) and Debulking
Surgery. The term IDS should be confined to patients
who have had primary surgical debulking, but it has been
used in situations whereby a primary surgical attempt is
delayed until during chemotherapy. Six large case-control
studies [10–15] relating to “delayed” primary surgery were
identified, and are summarized in Table 2.
One of the studies [10, Colombo et al.] divided patients
into 2 groups to evaluate the place of surgery in the
therapeutic sequence of care: group 1 receiving upfront
surgery and group 2 where first debulking was undertaken
after chemotherapy. In group 1 the OS was 38 months and
3 factors significantly predicted suboptimal upfront surgery:
poor performance status, extensive mesenteric involvemen,
and stage IV disease. The second group showed OS of 26
months, and despite a response to NACT in 90% of cases,
there was no long-term survivors in the patients whose
interval cytoreduction was suboptimal. Generally, OS was
stated to be influenced by three main factors: the extent
of the disease at the time of diagnosis, the biology of the
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tumour, and its chemosensitivity, and the authors concluded
that optimal surgery with limited morbidity (14% in their
case) can be achieved in many cases at primary surgery
setting. Hegazy et al. [12] found, in a population of patients
with advanced ovarian carcinoma where resectability was
not possible, that neoadjuvant chemotherapy helped to select
patients for feasible and relatively less aggressive IDS, thus
preventing initial surgical failure, in terms of optimal debulk-
ing. However, Morris et al. [27] in 1989 demonstrated that
patients resistant to chemotherapy during primary treatment
had little benefit from IDS. This was also concluded by Rafii
et al. [14] as well as the selection eﬀect of NACT for the
second intention surgery.
In another recent study [13], the complete response
rates after three cycles of platinum/taxane chemotherapy was
36.1%. After IDS, 80% of all patients were left with optimal
residuals (<2 cms). The response rate to chemotherapy given
in a neoadjuvant setting was comparable to those published
in literature in patients who were treated with conventional
upfront tumour reduction surgery followed by adjuvant
chemotherapy. They also found that residual decease after
IDS is the only significant predictive factor associated with
prolonged PFS (P = .003). To date, there is very little
good quality evidence to either support or refute the use
of neoadjuvant chemotherapy in the treatment of ovarian
cancer [9].
A retrospective study between 1980 and 1997 from
Vergote et al. [15] included 285 patients with stages III
and IV ovarian cancer. In the period from 1980 to 1988,
optimal primary cytoreduction (0.5 cm residual disease)
was achieved in 82% of cases, but patients with stage IV
disease or a metastatic tumour load of >1 kg prior to
this procedure had poorer survival with high postoperative
mortality (6%). Between 1989 and 1997 patients received
either upfront surgery or chemotherapy depending on the
extent of the disease and the performance status. This
subsequent management improved overall survival, despite
a reduction of 25% in the rate of primary debulking.
4.4. Surgery at Relapsed Disease. A large Norwegian retro-
spective study (n = 789) [11] carried out at the Radium
Hospital looked at treatment model for 1st relapse of ovarian
cancer of any stage. They found that treatment free interval
(TFI) following primary therapy is a significant prognostic
factor for OS in multivariate analysis. They also report
age as prognostic factor for OS at the time of secondary
cytoreductive surgery. Survival benefit was clear for patients
with optimum secondary cytoreductive surgery followed
by chemotherapy compared with chemotherapy alone at
the time of recurrence. Complete secondary cytoreductive
surgery was found possible in a significant percentage
of patients properly selected for this secondary surgery.
Localised tumour was found to be a significant factor to
predict this optimum surgery. This selection of patients for
secondary cytoreductive surgery is thus crucial. Guidelines at
relapse [11] for local and disseminated disease have been set
up, where secondary cytoreductive surgery is recommended
as independent of TFI for localized tumours and should be
Table 3: Radium hospital guidelines for IDS based on TFI and
number of recurrence sites, taken from Oksefjell et al. 2009 [11].
TFI, months Local disease Disseminated disease
0–5 Consider SCR No SCR
6–11 Oﬀer SCR No SCR
12–23 Oﬀer SCR No SCR
>24 Oﬀer SCR Consider SCR
SCR: secondary cytoreduction; TFI: treatment-free interval.
considered for TFI > 24 months in case of disseminated
disease (Table 3).
Selecting the right patients for the right treatment
sequence is challenging. Predicting the possibility to perform
successful surgery has been studied [28, 29] with one model
having an 85% specificity or ability to identify patients
undergoing optimal surgery [30]. In certain situations
laparoscopy is recommended as the most valuable tool
for evaluating the operability in upfront or second line
debulking surgery [31].
5. Conclusions
This paper has reviewed only RCTs and large series, which
do reflect the findings of many other reports on the specific
debates surrounding the role and timing of surgery in
ovarian carcinoma. There is agreement that one of the most
important prognostic factors for survival in the treatment
of ovarian cancer is the amount of residual tumour after
cytoreduction [4, 16]. It is welcome to note that in more
recent times surgical approaches have undergone scrutiny
in RCTs. Indeed there is evidence of a shift from debulking
for all to debulking for a select group, or put another way
increased individualisation of therapy. Unlike in previous
decades the use of neoadjuvant chemotherapy seems to have
gained some popularity, though the real impact requires the
formal publication of the randomized trials EORTC 55971
and CHORUS. The EORTC study has been presented at the
IGCS in Bangkok and generated a lot of debate, as to the role
of neoadjuvant chemotherapy. The finalised peer-reviewed
publication is awaited with interest.
Another factor which cannot be ignored in the debate
is the inherent tumour biology where the question, raised
by some [32] and still requiring an answer, is to know if it
is the surgeon’s skills or tumour biology which determines
survival outcome. In this respect, opinions vary regarding
its impact on the ability to surgically debulk [21]. On the
other hand, others have put forward the strong expression
of the p53 tumour suppressor gene correlating with reduced
likelihood of achieving complete cytoreduction [33]. The
progress and accessibility to novel technologies applied to
biology will make possible in the future the assessment of
new prognostic profilesbased on genetic and/or proteomic
tumour characteristics. The future also relies on the identi-
fication of predictive factors of response to treatment [34].
Journal of Oncology 5
References
[1] J. Permuth-Wey and T. A. Sellers, “Epidemiology of ovarian
cancer,” Methods in Molecular Biology, vol. 472, pp. 413–437,
2009.
[2] R. W. Hunter, N. D. E. Alexander, and W. P. Soutter,
“Meta-analysis of surgery in advanced ovarian carcinoma: is
maximum cytoreductive surgery an independent determinant
of prognosis?” American Journal of Obstetrics and Gynecology,
vol. 166, no. 2, pp. 504–511, 1992.
[3] D. G. Allen, A. P. M. Heintz, and F. W. M. M. Touw, “A meta-
analysis of residual disease and survival in stage III and IV
carcinoma of the ovary,” European Journal of Gynaecological
Oncology, vol. 16, no. 5, pp. 349–356, 1995.
[4] R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble,
and F. J. Montz, “Survival eﬀect of maximal cytoreductive
surgery for advanced ovarian carcinoma during the platinum
era: a meta-analysis,” Journal of Clinical Oncology, vol. 20, no.
5, pp. 1248–1259, 2002.
[5] M. E. L. van der Burg, M. van Lent, M. Buyse, et al., “The eﬀect
of debulking surgery after induction chemotherapy on the
prognosis in advanced epithelial ovarian cancer. Gynecological
Cancer Cooperative Group of the European Organization for
Research and Treatment of Cancer,” The New England Journal
of Medicine, vol. 332, no. 10, pp. 629–634, 1995.
[6] P. G. Rose, S. Nerenstone, M. F. Brady, et al., “Secondary
surgical cytoreduction for advanced ovarian carcinoma,” The
New England Journal of Medicine, vol. 351, no. 24, pp. 2489–
2497+2567, 2004.
[7] C. W. E. Redman, J. Warwick, D. M. Luesley, R. Varma, F.
G. Lawton, and G. R. P. Blackledge, “Intervention debulking
surgery in advanced epithelial ovarian cancer,” British Journal
of Obstetrics and Gynaecology, vol. 101, no. 2, pp. 142–146,
1994.
[8] S. Tangjitgamol, S. Manusirivithaya, M. Laopaiboon, and
P. Lumbiganon, “Interval debulking surgery for advanced
epithelial ovarian cancer,” Cochrane Database of Systematic
Reviews, no. 2, Article ID CD006014, 2009.
[9] J. Morrison, A. Swanton, S. Collins, and S. Kehoe,
“Chemotherapy versus surgery for initial treatment in
advanced ovarian epithelial cancer,” Cochrane Database of
Systematic Reviews, no. 4, Article ID CD005343, 2007.
[10] P.-E. Colombo, A. Mourregot, M. Fabbro, et al., “Aggressive
surgical strategies in advanced ovarian cancer: a monocentric
study of 203 stage IIIC and IV patients,” European Journal of
Surgical Oncology, vol. 35, no. 2, pp. 135–143, 2009.
[11] H. Oksefjell, B. Sandstad, and C. Trope´, “The role of secondary
cytoreduction in the management of the first relapse in
epithelial ovarian cancer,” Annals of Oncology, vol. 20, no. 2,
pp. 286–293, 2009.
[12] M. A. F. Hegazy, R. A. F. Hegazi, M. A. Elshafei, et al., “Neoad-
juvant chemotherapy versus primary surgery in advanced
ovarian carcinoma,” World Journal of Surgical Oncology, vol.
3, article 57, 2005.
[13] T. Le, W. Faught, L. Hopkins, and M. Fung-Kee-Fung, “Can
surgical debulking reverse platinum resistance in patients with
metastatic epithelial ovarian cancer?” Journal of Obstetrics and
Gynaecology Canada, vol. 31, no. 1, pp. 42–47, 2009.
[14] A. Rafii, B. Deval, J.-F. Geay, et al., “Treatment of FIGO stage
IV ovarian carcinoma: results of primary surgery or inter-
val surgery after neoadjuvant chemotherapy: a retrospective
study,” International Journal of Gynecological Cancer, vol. 17,
no. 4, pp. 777–783, 2007.
[15] I. Vergote, I. De Wever, W. Tjalma, M. Van Gramberen, J.
Decloedt, and P. van Dam, “Neoadjuvant chemotherapy or
primary debulking surgery in advanced ovarian carcinoma: a
retrospective analysis of 285 patients,” Gynecologic Oncology,
vol. 71, no. 3, pp. 431–436, 1998.
[16] C. T. Griﬃths, “Surgical resection of tumor bulk in the
primary treatment of ovarian carcinoma,” National Cancer
Institute Monograph, vol. 42, pp. 101–104, 1975.
[17] I. T. Magrath, S. Lwanga, W. Carswell, and N. Harrison, “Sur-
gical reduction of tumour bulk in management of abdominal
Burkitt’s lymphoma,” British Medical Journal, vol. 2, no. 914,
pp. 308–312, 1974.
[18] C. T. Griﬃths and A. F. Fuller, “Intensive surgical and
chemotherapeutic management of advanced ovarian cancer,”
Surgical Clinics of North America, vol. 58, no. 1, pp. 131–142,
1978.
[19] A. L. Covens, “A critique of surgical cytoreduction in advanced
ovarian cancer,” Gynecologic Oncology, vol. 78, no. 3, pp. 269–
274, 2000.
[20] W. J. Hoskins, B. N. Bundy, J. T. Thigpen, and G. A. Omura,
“The influence of cytoreductive surgery on recurrence-free
interval and survival in small-volume stage III epithelial ovar-
ian cancer: a Gynecologic Oncology Group study,” Gynecologic
Oncology, vol. 47, no. 2, pp. 159–166, 1992.
[21] S. M. Eisenkop and N. M. Spirtos, “Procedures required to
accomplish complete cytoreduction of ovarian cancer: is there
a correlation with “biological aggressiveness” and survival?”
Gynecologic Oncology, vol. 82, no. 3, pp. 435–441, 2001.
[22] D. S. Chi, E. L. Eisenhauer, J. Lang, et al., “What is the optimal
goal of primary cytoreductive surgery for bulky stage IIIC
epithelial ovarian carcinoma (EOC)?” Gynecologic Oncology,
vol. 103, no. 2, pp. 559–564, 2006.
[23] W. J. Hoskins, “Epithelial ovarian carcinoma: principles of
primary surgery,” Gynecologic Oncology, vol. 55, no. 3, pp. S91–
S96, 1994.
[24] S. M. Eisenkop, N. M. Spirtos, and W.-C. M. Lin, ““Optimal”
cytoreduction for advanced epithelial ovarian cancer: a com-
mentary,” Gynecologic Oncology, vol. 103, no. 1, pp. 329–335,
2006.
[25] J. S. Berek, N. F. Hacker, L. D. Lagasse, R. K. Nieberg, and R.
M. Elashoﬀ, “Survival of patients following secondary cytore-
ductive surgery in ovarian cancer,” Obstetrics and Gynecology,
vol. 61, no. 2, pp. 189–193, 1983.
[26] S. Kehoe, J. Powell, S. Wilson, and C. Woodman, “The
influence of the operating surgeon’s specialisation on patient
survival in ovarian carcinoma,” British Journal of Cancer, vol.
70, no. 5, pp. 1014–1017, 1994.
[27] M. Morris, D. M. Gershenson, and J. T. Wharton, “Secondary
cytoreductive surgery in epithelial ovarian cancer: nonrespon-
ders to first-line therapy,” Gynecologic Oncology, vol. 33, no. 1,
pp. 1–5, 1989.
[28] D. S. Chi, E. S. Venkatraman, V. Masson, and W. J. Hoskins,
“The ability of preoperative serum CA-125 to predict optimal
primary tumor cytoreduction in stage III epithelial ovarian
carcinoma,” Gynecologic Oncology, vol. 77, no. 2, pp. 227–231,
2000.
[29] S. Memarzadeh, S. B. Lee, J. S. Berek, and R. P. Farias-Eisner,
“CA125 levels are a weak predictor of optimal cytoreductive
surgery in patients with advanced epithelial ovarian cancer,”
International Journal of Gynecological Cancer, vol. 13, no. 2, pp.
120–124, 2003.
[30] R. E. Bristow, L. R. Duska, N. C. Lambrou, et al., “A model for
predicting surgical outcome in patients with advanced ovarian
6 Journal of Oncology
carcinoma using computed tomography,” Cancer, vol. 89, no.
7, pp. 1532–1540, 2000.
[31] I. Vergote, T. van Gorp, F. Amant, K. Leunen, P. Neven, and P.
Berteloot, “Timing of debulking surgery in advanced ovarian
cancer,” International Journal of Gynecological Cancer, vol. 18,
supplement 1, pp. 11–19, 2008.
[32] S. Kehoe, “Maximal cytoreductive surgery in advanced ovarian
cancer,” Reviews in Gynaecological Practice, vol. 5, no. 4, pp.
207–211, 2005.
[33] G. H. Eltabbakh, S. L. Mount, B. Beatty, L. Simmons-
Arnold, K. Cooper, and A. Morgan, “Factors associated with
cytoreducibility among women with ovarian carcinoma,”
Gynecologic Oncology, vol. 95, no. 2, pp. 377–383, 2004.
[34] P. Boudou-Rouquette, P. Pautier, P. Morice, and C. Lhomme´,
“Prognostic and predictive factors in epithelial ovarian can-
cer,” Bulletin du Cancer, vol. 96, no. 4, pp. 425–437, 2009.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
